Skip to Content
Merck
CN

Z2001

Zonisamide sodium salt

≥98% (HPLC), NO scavenger, powder

Synonym(s):

1,2-Benzisoxazole-3-methanesulfonamide sodium-potassium salt, Aleviatin sodium-potassium salt, Exceglan sodium-potassium salt, Excegram sodium-potassium salt

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C8H7N2NaO3S
CAS Number:
68291-98-5
Molecular Weight:
234.21
UNSPSC Code:
12352200
PubChem Substance ID:
24278783
NACRES:
NA.77
MDL number:
MFCD01744844

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Zonisamide sodium salt, ≥98% (HPLC), powder

SMILES string

[Na]NS(=O)(=O)Cc1noc2ccccc12

InChI key

ZVBIRPKGWOVBLG-UHFFFAOYSA-N

InChI

1S/C8H7N2O3S.Na/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7;/h1-4H,5H2,(H-,9,11,12);/q-1;+1

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

H2O: >5 mg/mL

originator

Eisai

Quality Level

100

Gene Information

human ... SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335)

Related Categories

Features and Benefits

This compound was developed by Eisai. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Biochem/physiol Actions

Zonisamide sodium salt is an anti-epileptic and also scavenges nitric oxide (NO).
Zonisamide sodium salt is an anti-epileptic. It is effective in various animal epilepsy models and humans with both partial and generalized epileptic seizures. Zonisamide sodium salt also scavenges nitric oxide (NO).

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000166036
0000166037
092M4607V
0000166037
0000166036

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M E Choudhury et al.
European journal of pharmacology, 689(1-3), 72-80 (2012-06-05)
Zonisamide has been proven as an effective drug for the recovery of degenerating dopaminergic neurons in the animal models of Parkinson's disease. However, several lines of evidence have questioned the neuroprotective capacity of zonisamide in animal models of Parkinson's disease.
Kyoung Heo et al.
Seizure, 21(3), 188-193 (2012-01-10)
To evaluate the efficacy and safety of adjunctive zonisamide (ZNS) therapy in Korean adults with uncontrolled partial epilepsy. Study patients had an average of at least one seizure per 4-week (averaged over a 12-week historical baseline) despite the use of
D Marazziti et al.
European review for medical and pharmacological sciences, 16(15), 2102-2107 (2013-01-03)
Binge-eating disorder (BED) is a relatively new disorder characterized by binge eating without purging. The purpose of this article is to review the potential use of the recently proposed compounds for the treatment of BED. A medline of published articles
Kouji Fukuyama et al.
Pharmaceuticals (Basel, Switzerland), 13(6) (2020-06-11)
Recent studies using the genetic partial epilepsy model have demonstrated that hyperfunction of astroglial hemichannels contributes to pathomechanism of epileptic seizure. Therefore, to explore the novel anticonvulsive mechanisms, the present study determined the effects of voltage-dependent Na+ channel (VDSC)-inhibiting anticonvulsants
S Dupont et al.
Acta neurologica Scandinavica. Supplementum, (194)(194), 29-35 (2012-11-01)
Zonisamide is currently licensed in Europe and the USA for the adjunctive treatment of partial seizures (with or without secondary generalization) in adults, based on the results of four pivotal, randomized, double-blind, placebo-controlled trials. It is also licensed in Europe
View All Related Papers

Related Content

Data Sheet - Z2001

Instructions

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service